Eledon Pharmaceuticals
ELDN
34 hedge funds and large institutions have $74.5M invested in Eledon Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 6 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 7
7.73% more ownership
Funds ownership: 58.13% → 65.85% (+7.7%)
0% more funds holding
Funds holding: 34 → 34 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
16% less capital invested
Capital invested by funds: $89M → $74.5M (-$14.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$10.5M |
| 2 |
Morgan Stanley
New York
|
+$7.92M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$943K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$601K |
| 5 |
Two Sigma Advisers
New York
|
+$568K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$11.9M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$371K |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$317K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$268K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$238K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SWM
26
Spire Wealth Management
Mclean,
Virginia
| $7K | +$4.72K | +500 | +143% |
|
|
CSS
27
Cubist Systematic Strategies
Stamford,
Connecticut
| $5K | -$3.77K | -400 | -40% |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| $5K | +$6.07K | +643 | New |
|
29
Wells Fargo
San Francisco,
California
| $1K | -$9 | -1 | -1% |
|
30
JP Morgan Chase
New York
| $1K | +$623 | +66 | New |
|
31
Bank of America
Charlotte,
North Carolina
| $1K | +$1.33K | +141 | New |
|
|
EC
32
EcoR1 Capital
San Francisco,
California
| – | -$11.9M | -1,115,721 | Closed |
|
|
33
Citadel Advisors
Miami,
Florida
| – | -$268K | -25,062 | Closed |
|
|
34
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$238K | -22,247 | Closed |
|
|
ECM
35
ExodusPoint Capital Management
New York
| – | -$190K | -17,773 | Closed |
|
36
Citigroup
New York
| – | -$23K | -2,166 | Closed |
|
|
PAM
37
Panagora Asset Management
Boston,
Massachusetts
| – | -$9 | -1 | -5% |
|
38
Simplex Trading
Chicago,
Illinois
| – | +$330 | +35 | New |
|
ELDN Hedge Fund Activity: Q2 2021 in Review
34 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q2 2021, worth a combined $74.5M — down 16% from $89M a quarter earlier.
Fund positioning in ELDN was balanced in Q2 2021: 6 funds opened new positions, 6 closed out, 13 added to existing stakes and 7 trimmed.
The largest buyer was Logos Global Management, adding an estimated $10.5M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $11.9M sold.
- 34 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $74.5M of Eledon Pharmaceuticals stock for Q2 2021, down 16% quarter-over-quarter.
- 6 funds opened new Eledon Pharmaceuticals positions in Q2 2021 and 6 closed out, a net change of 0 holders.
- The largest Eledon Pharmaceuticals buyer in Q2 2021 was Logos Global Management, an estimated $10.5M added.
- The largest Eledon Pharmaceuticals seller in Q2 2021 was EcoR1 Capital, an estimated $11.9M sold.
Based on aggregated 13F filings for Q2 2021.